Brief: Cohbar Inc Announces Preclinical Collaboration With NIAID To Evaluate Potential Of CB5064 Analogs For Treatment Of Covid-19 ARDS
11/01/2021 14:50
Jan 11 (Reuters) - CohBar Inc CWBR.O :
* COHBAR INC - ANNOUNCES PRECLINICAL COLLABORATION WITH
NIAID TO
EVALUATE POTENTIAL OF CB5064 ANALOGS FOR TREATMENT OF COVID-19
ARDS
Source text for Eikon: ID:nGNX89PJ8
Further company coverage: CWBR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CohBar
See all newsBrief: CohBar, Inc. Q2 EPS USD -1.49
Brief: Morphogenesis And CohBar Announce Positive Results From Phase 1B Trial Of IFX-HU2.0 Personalized Cancer Vaccine, In Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) And Cutaneous Squamous Cell Carcinoma (CSCC)
U.S. STOCKS ON THE MOVE-Galecto, Pinterest, Standard Lithium
CohBar surges on merger agreement with Morphogenesis
U.S. STOCKS ON THE MOVE-Chevron, Broadcom, Williams-Sonoma